Development and clinical validation of a quantitative mass spectrometric assay for PD-L1 protein in FFPE NSCLC samples

被引：0
|
作者：
An, E. [1 ]
Liao, W. [1 ]
Thyparambil, S. [1 ]
Rodriguez, J. [2 ]
Salgia, R. [3 ]
Wistuba, I. [2 ]
Burrows, J. [1 ]
Hembrough, T. [1 ]
机构：
[1] OncoPlex Diagnost, Rockville, MD USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Chicago, Chicago, IL 60637 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)70615-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
489
引用
收藏
页码：159 / 159
页数：1
相关论文
共 50 条
  • [31] PREVALENCE AND PROGNOSTIC ASSOCIATION OF PD-L1 PROTEIN AND IMMUNE GENE EXPRESSION IN NSCLC
    Kowanetz, Marcin
    Shames, David S.
    Koeppen, Hartmut
    Xiao, Yuanyuan
    Behrens, Carmen
    Desai, Rupal
    Fu, Ling
    Chappey, Colombe
    Mokatrin, Ahmad
    Kadel, Edward E.
    Do, An
    Brustugun, Odd Terje
    D'Arcangelo, Manolo
    Boyle, Theresa
    Chen, Daniel S.
    Hampton, Garret
    Amler, Lukas C.
    Hirsch, Fred R.
    Hegde, Priti S.
    Wistuba, Ignacio I.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S377 - S377
  • [32] PD-L1 Very High Expression Associated with Clinical Outcome of Pembrolizumab Monotherapy of Advanced NSCLC with PD-L1 TPS of 50% or Greater
    Itani, H.
    Nigi, A.
    Iwamoto, K.
    Ito, Y.
    Tanigawa, M.
    Kondo, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S662 - S663
  • [33] In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1
    Zhai, Wenjie
    Zhou, Xiuman
    Du, Jiangfeng
    Gao, Yanfeng
    TUMOR IMMUNOLOGY AND IMMUNOTHERAPY - MOLECULAR METHODS, 2019, 629 : 361 - 381
  • [34] High tumoral IFNγ mRNA, PD-L1 protein, and combined IFNγ mRNA/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) monotherapy in NSCLC patients
    Higgs, B. W.
    Robbins, P. B.
    Blake-Haskins, J. A.
    Zhu, W.
    Morehouse, C.
    Brohawn, P. Z.
    Rebelatto, M. C.
    Yao, Y.
    Jin, X.
    Shi, L.
    Ranade, K.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S717 - S717
  • [35] Quantitative immunohistochemical assay with novel digital immunostaining for comparisons of PD-L1 antibodies
    Fujisawa, Takuo
    Tsuta, Koji
    Yanagimoto, Hiroaki
    Yagi, Masao
    Suzuki, Kensuke
    Nishikawa, Kenji
    Takahashi, Masaru
    Okada, Hisatake
    Nakano, Yasushi
    Iwai, Hiroshi
    MOLECULAR AND CLINICAL ONCOLOGY, 2019, 10 (03) : 391 - 396
  • [36] Biological and clinical relevance of PD-L1 expression in tumor and inflammatory cells in NSCLC
    Bais, Carlos
    Morehouse, Chris
    Higgs, Brandon W.
    Marlon, Rebelatto
    Steele, Keith
    Jin, Xiaoping
    Shi, Li
    Korolevich, Susana
    Gupta, Ashok
    Ranade, Koustubh
    CANCER RESEARCH, 2017, 77
  • [37] Validation Study of Ventana SP263 PD-L1 Immunohistochemistry Antibody Assay as LDT for Clinical Use in patients with NSCLC being considered for Keytruda Therapy
    Marolt, Monna
    Racila, Emilian
    LABORATORY INVESTIGATION, 2019, 99
  • [38] Development and validation of longitudinal c-reactive protein as dynamic response predictor for PD-L1 blockade in advanced NSCLC: Findings from four atezolizumab clinical trials.
    Zhou, Jian-Guo
    Chen, Xiaofei
    Wong, Ada Hang-Heng
    Wang, Haitao
    Tan, Fangya
    He, Si-Si
    Shen, Gang
    Wang, YunJia
    Wang, Ruihong
    Carr, Shamus R.
    Frey, Benjamin
    Fietkau, Rainer
    Hecht, Markus
    Ma, Hu
    Schrump, David S.
    Gaipl, Udo S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] Validation Study of Ventana SP263 PD-L1 Immunohistochemistry Antibody Assay as LDT for Clinical Use in patients with NSCLC being considered for Keytruda Therapy
    Marolt, Monna
    Racila, Emilian
    MODERN PATHOLOGY, 2019, 32
  • [40] Copy-number profiling of single, digitally-sorted PD-L1 positive cells in NSCLC FFPE tissues
    Bassi, Giulio
    Bolognesi, Chiara
    Mangano, Chiara
    Forcato, Claudio
    Ferrarini, Alberto
    Del Monaco, Valentina
    Tononi, Paola
    Buson, Genny
    Medoro, Gianni
    Nicolo, Manaresi
    Fontana, Francesca
    CANCER RESEARCH, 2017, 77
12345